stem cell transplantation

Allogeneic Stem Cell Transplantation Improves Survival in High-Risk t(6;9) AML, Especially in Younger Patients and Those Achieving CR1

By MedXY 04/27/2026

A large EBMT study shows allo-HSCT provides favorable 2-year survival (65.7%) in high-risk t(6;9) AML, with superior outcomes in CR1 and pediatric/AYA patients. FLT3-ITD positivity triples relapse risk but doesn't impact overall survival.

Hematology-Oncology news

Predictive Value of Sex Chromosome Loss in Sex-Mismatched Stem Cell Transplantation

By MedXY 03/25/2026

This study identifies late-onset sex chromosome loss as a critical biomarker for predicting relapse and survival outcomes in patients following sex-mismatched stem cell transplantation.

Clinical Updates Hematology-Oncology news Specialties

Haematopoietic Gene Therapy Without Conditioning for Fanconi Anaemia-A: Results and Clinical Implications from the FANCOLEN-1 Trials

By MedXY 08/02/2025

Gene therapy using autologous, gene-corrected stem cells without conditioning offers sustained engraftment and reverses bone marrow failure in Fanconi anaemia-A, with a favorable safety profile.

Clinical Updates Hematology-Oncology news Specialties

Advances in Graft-versus-Host Disease Prophylaxis: Cyclophosphamide and Cyclosporin in Allogeneic Stem Cell Transplantation

By MedXY 08/01/2025

Post-transplant cyclophosphamide plus cyclosporin significantly improves GVHD-free, relapse-free survival compared to standard prophylaxis in matched related donor stem cell transplantation.